PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34427649-1	2022	BACKGROUND: The first-in-class treatment PF-06480605 targets the tumor necrosis factor-like ligand 1A (TL1A) molecule in humans.	pf-06480605	41-52	TNF superfamily member 15	Homo sapiens	65-101	
34427649-1	2022	BACKGROUND: The first-in-class treatment PF-06480605 targets the tumor necrosis factor-like ligand 1A (TL1A) molecule in humans.	pf-06480605	41-52	TNF superfamily member 15	Homo sapiens	103-107	
34427649-8	2022	CONCLUSIONS: The ability of PF-06480605 to engage and inhibit colonic TL1A, targeting inflammatory T cell and fibrosis pathways, provides the first-in-human mechanistic data to guide anti-TL1A therapy for the treatment of IBD.	pf-06480605	28-39	TNF superfamily member 15	Homo sapiens	70-74	
34427649-8	2022	CONCLUSIONS: The ability of PF-06480605 to engage and inhibit colonic TL1A, targeting inflammatory T cell and fibrosis pathways, provides the first-in-human mechanistic data to guide anti-TL1A therapy for the treatment of IBD.	pf-06480605	28-39	TNF superfamily member 15	Homo sapiens	188-192